Work In Collaboration With Excellence

Our team is staffed by highly experienced scientists (over 80% PhDs), many with 10-20 years of drug discovery experience gained in pharmaceutical research (from AstraZeneca, Takeda, GSK, Merck, Novartis, Pfizer, Prosidion and many more).  More than 25% of the department has over 15 years’ first-hand industry experience in discovering new drugs, both small molecules and biologicals across a broad range of therapeutic areas and biological target classes.  Your drug discovery projects are in safe hands at Sygnature Discovery.

Our experts specialise in seven key areas:

Assay Development

Implement and maintain your project-tailored in vitro screening cascades based on decades of experience, providing assay development services from Target Validation through to Lead Optimisation and candidate nomination.

Cellular Assays

2D and 3D cellular assays providing real-time and high-resolution end points to assess the impact of your target on multiple phenotypic endpoints.

Biophysical Assays

Our biophysicists are able to employ the latest technologies to characterise compound binding interactions at all stages of drug discovery.

Primary Tissues

We have a Human Tissue Act (HTA) accreditation, an internal blood donor panel and access to human and animal primary tissues from accredited biobanks and commercial vendors to provide physiologically relevant support to your project.

Drug Screening

Scalable hit identification screening methodologies from high-content to fragment screens. Bespoke, efficient screening assays can be developed to support discovery programs in a wide variety of areas.

Biochemical Assays

Tailored biochemical assay development service utilising multiple assay formats in order to provide assays most relevant to your drug discovery venture.

Biomarker Discovery

We have a diverse range of sensitive biomarker detection platforms and assays that can be used to develop and validate biomarkers for your drug target.

In_Vitro_Screening_Strategies_For_Drug_Discovery

Download our latest eBook

As you start to consider what an appropriate screening cascade should look like, it is important to define what key properties you are looking for in your candidate drug, as these will impact the choice of assays you may deploy in your screening cascade. This eBook describes some key factors worth considering as you think through how to construct an effective and robust screening cascade. We will focus initially on the hit-to-lead phase, as this encompasses the types of assays required and highlights some general considerations. Following this, we will explore some of the key differences in screening cascades as the project moves into the lead optimization phase.

Download My eBook

Delivering for our customers - a proven track record

  • 48 pre-clinical candidates delivered
  • 27 already progressed to clinical trials (>50%)
  • Sygnature Discovery co-inventors named on >170 client patent applications
Performance graph only (with atom filigrane)-1

Discover your next project's potential

Discover More